With the amazing successes that have been reported over the past 10 years, it is easy for researchers in therapeutic ultrasound to be seduced by the appeal of biological and clinical studies - but understanding the biology alone is insufficient. All good science requires repeatability, and developing a successful therapy is no different. It is imperative from both a scientific and a commercial perspective that we can not only demonstrate the interaction of ultrasound with biological systems but also quantify the relationship between the delivered ultrasound and the biological effect. Moreover, we then need to be able to control the delivered ultrasound - the ultrasound dose, if you like - to achieve consistent and repeatable treatments.

A distinguishing feature of our new journal - whose stated goal is to 'accelerate the adoption of therapeutic ultrasound as a clinical tool' - should be an insistence that best practice is followed first when planning the ultrasound exposure regime and again when reporting those conditions. We should set a clear example for other journals, and for funding bodies, to follow. This will make it apparent, even to those researchers who are not primarily interested in physics and engineering, that knowledge and control of the delivered ultrasound is not something that can be ignored until writing the final paper. It absolutely must be built into a study even before the proposal is submitted. Too often, even in high-quality and esteemed journals, the exposure description is inadequate, and assumptions (for instance, about the mechanism of interaction) are not pro perly explained. The researchers themselves may often not be fully aware of these weaknesses in their study.

It is our belief that a handful of simple guidelines \[[@B1]\] published by the authors of this piece will serve to remind researchers of the importance of good ultrasound measurement and exposure estimation and will lead over time to a greater body of research which can be replicated and tested by others. Our starting principles in preparing these guidelines were simple enough: firstly, that for a quantitative exposure-response study, there must be some measurements of the actual ultrasound field or fields used; and secondly, that the measured values (usually in water, following methods described in international standards) must be reported, and the methods for estimating any other *in situ* or exposure quantities must be clearly laid out. Of course it is true that the ultrasound field measured in water may be very different from the field in tissue or the sample holder *in vitro*. Nevertheless, having a proper description of the undisturbed field is the first step to understanding the experimental conditions and to being able to replicate the exposure. Taken together, these two principles will help avoid many of the potential misunderstandings that can arise.

The full set of recommendations and example wording are discussed in detail in \[[@B1]\]. As well as reading these, authors and reviewers for our journal should ask themselves some simple questions at all stages of their work.

Q1. Does this study attempt to demonstrate correlation between exposure to ultrasound and a physical or biological effect? If it does, it must include acoustic output measurements of the ultrasound field to determine maximum values in the field or, preferably, the acoustic pressure and intensity distributions.

Q2. Are the measured values of output power, acoustic pressure, intensity, and other acoustic quantities reported? Have the measurement methods been described in sufficient detail to be replicated by others?

Q3. Has the temperature rise in the region of the cells or tissue of interest (or in a suitable substitute) been measured and reported, even if a thermal mechanism is not being tested?

Q4. If estimated values of *in situ* acoustic pressure or intensity are reported (for instance by using a 'derating' factor), has the method for calculating the *in situ* value been fully explained, and a worked example given? Is the estimated transmission loss in the propagation path reasonable?

Q5. If a thermal or mechanical index is calculated for use as an exposure quantity, has a reasonable value for the attenuation coefficient of the propagation path been used as the derating factor? Has the calculation been stated mathematically and a worked example given?

Asking - and answering! - these questions will help produce a rigorous study which will provide a solid basis for conclusions and for future work. Let us start as we mean to go on with our own journal and demand the highest standards of measurement and reporting of ultrasound fields and exposure levels.
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